Abstract
Intervention strategies for minimizing indoor SARS-CoV-2 transmission are often based on anecdotal evidence because there is little evidence-based research to support them. We developed a spatially-explicit agent-based model for simulating indoor respiratory pathogen transmission, and used it to compare effects of four interventions on reducing individual-level SARS-CoV-2 transmission risk by simulating a well-known case study. We found that imposing movement restrictions and efficacious mask usage appear to have the greatest effects on reducing infection risk, but multiple concurrent interventions are required to minimize the proportion of susceptible individuals infected. Social distancing had little effect on reducing transmission if individuals move during the gathering. Furthermore, our results suggest that there is potential for ventilation airflow to expose susceptible people to aerosolized pathogens even if they are relatively far from infectious individuals. Maximizing rates of aerosol removal is the key to successful transmission-risk reduction when using ventilation systems as intervention tools.
Article Summary Line Imposing mask usage requirements, group size restrictions, duration limits, and social distancing policies can have additive, and in some cases multiplicative protective effects on SARS-CoV-2 infection risk during indoor events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by CDC U01CK000587-01M001 and R35GM134934.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The model referred to in our manuscript is available for download at https://github.com/lanzaslab/droplet-ABM.
